Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?
UroGen Pharma (NASDAQ:URGN) operates as a specialized oncology and urology therapeutics company anchored by proprietary sustained-release technology platforms.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 2,434,207 | $89,578,818 | +9% | 4.95% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 2,199,652 | $80,947,194 | 0.53% | |
| 3. | Point72 Asset Management Steve Cohen | 1,525,549 | $56,140,203 | 0.06% | |
| 4. | Opaleye Management James A. Silverman | 1,439,996 | $52,991,853 | +1% | 4.8% |
| 5. | SilverArc Capital Devesh Gandhi | 1,301,979 | $47,912,827 | -14% | 4.98% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.10 | 160 | $2,096.00 | 21,997 | 2021-11-18 | Filing | |
| $15.85 | 2,500 | $39,625.00 | 2,500 | 2021-05-17 | Filing | |
| $15.71 | 2,500 | $39,275.00 | 2,500 | 2021-05-17 | Filing | |
| $18.50 | 10,000 | $185,000.00 | 229,117 | 2020-12-14 | Filing | |
| $28.00 | 7,530 | $210,840.00 | 16,548 | 2019-11-21 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.69 | 2,202 | $80,791.38 | 4,561 | 2026-10-08 | Filing | |
| $42.92 | 871 | $37,383.32 | 59,882 | 2026-09-08 | Filing | |
| $42.54 | 1,519 | $64,618.26 | 53,141 | 2026-09-08 | Filing | |
| $47.05 | 60,677 | $2,854,852.85 | 59,086 | 2026-08-20 | Filing | |
| $40.00 | 10,000 | $400,000.00 | 119,763 | 2026-07-09 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 309,584 | $12,578,398 | 0.37% | |
| 2. | 34,701 | $1,409,902 | 0.27% | |
| 3. | 20,291 | $750,361 | 0% | |
| 4. | 10,987 | $446,402 | 0.02% | |
| 5. | 7,696 | $312,688 | 0% |